Entering text into the input field will update the search result below

Durect files response to Posimir CRL; shares up 7% premarket

Jul. 17, 2019 8:44 AM ETDURECT Corporation (DRRX) StockDRRXBy: Douglas W. House, SA News Editor
  • DURECT (NASDAQ:DRRX) is up 7% premarket on average volume following its announcement that it has submitted its responses to the CRL it received from the FDA in February 2014 pertaining to its marketing application for pain med POSIMIR (bupivacaine) citing the need for more safety data.
  • The agency's action date in December 27.

Recommended For You

More Trending News

About DRRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
DRRX--
DURECT Corporation